Jun 17 |
Zymeworks ZW171 IND for mesothelin-expressing cancers cleared by FDA
|
Jun 17 |
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
|
Jun 15 |
Zymeworks (NASDAQ:ZYME) investors are sitting on a loss of 75% if they invested three years ago
|
Jun 10 |
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
|
May 5 |
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
May 3 |
Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript
|
May 2 |
Zymeworks files automatic mixed securities shelf
|
May 2 |
Zymeworks GAAP EPS of -$0.42 misses by $0.10, revenue of $10.03M misses by $6.4M
|
May 2 |
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
May 1 |
Zymeworks Q1 2024 Earnings Preview
|